Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 3Lung Neoplasms 2Carcinoma, Hepatocellular 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Pancreatic Neoplasms 1Glioblastoma 1Carcinoma, Squamous Cell 1

Interventions

Gemcitabine 295Fluorouracil 82Oxaliplatin 81130-nm albumin-bound paclitaxel 68Capecitabine 60Leucovorin 56Albumin-Bound Paclitaxel 54Radiotherapy 51Irinotecan 44Taxes 37Cisplatin 36Erlotinib Hydrochloride 34Radiosurgery 33pembrolizumab 29Docetaxel 27S 1 (combination) 26Bevacizumab 23folfirinox 22Nivolumab 21Magnetic Resonance Spectroscopy 17Cyclophosphamide 17Cetuximab 17irinotecan sucrosofate 16Radiation 16Drug Therapy 15Surgical Procedures, Operative 14Specimen Handling 11Biopsy 11durvalumab 10Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pancreatic Neoplasms × bavituximab × Clear all
NCT01272791 2017-04-19

Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer

Peregrine Pharmaceuticals

Phase 2 Completed
70 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡